NIKKEI 225
26,871.27 +379.30 (+1.43%) HANG SENG
22,158.07 +439.01 (+2.02%) CRUDE OIL
107.42 -0.20 (-0.19%) GOLD FUTURES
1,837.70 +7.40 (+0.40%) DOW
31,500.68 +823.28 (+2.68%) BTC-GBP
17,285.83 -298.98 (-1.70%)
Valneva SE (0OB3.L)
| Previous close | 14.06 |
| Open | 14.94 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 12.42 - 14.95 |
| 52-week range | 12.42 - 14.95 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 1.21B |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Valneva SE Declaration of shares and voting rights - Interim status at June 22, 2022
VALNEVA Declaration of shares and voting rights Interim status at June 22, 2022__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: June 27, 2022 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on wh
- Globe Newswire
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Saint Herblain (France), June 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age. With this approval, VLA2001 becomes the first COVID-1
- Globe Newswire
Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members
Saint-Herblain (France), June 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held yesterday in Paris. Among the adopted resolutions were approval of the 2021 financial statements, delegations for the management board to increase Valneva’s share capital and/or issue financial instruments, and the appointment, fo
